Harmony Biosciences Reports Third Quarter 2021 Financial Results and Business Updates WAKIX® (pitolisant) Net Revenue of $80.7 Million for Third Quarter 2021 Increase of 77% vs. the Same Period in 2020 Average Number of Patients on WAKIX Increased to ~3,500 Announced Inclusion of...

Harmony Biosciences Reports Second Quarter 2021 Financial Results and Business Updates WAKIX® (pitolisant) Net Revenue of $73.8 Million for Second Quarter 2021 vs. $38 Million for the Same Period in 2020 Initiated Phase 2 Clinical Trial in Patients with Myotonic Dystrophy Acquired...

Harmony Biosciences Reports First Quarter 2021 Results and Business Updates WAKIX® (pitolisant) Total Revenue of $59.7 Million for First Quarter 2021 Achieves Profitability with $7.4 Million Net Income Conference Call and Webcast to be Held Today at 8:30 a.m. ET  ...

Harmony Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results and Business Updates WAKIX® (pitolisant) Total Revenue of $160 Million for Full-Year 2020; $56 Million for Fourth Quarter 2020 Clinical Utility of WAKIX was Expanded with Additional Approval for Treatment of Cataplexy...

Harmony Biosciences Reports Third Quarter 2020 Financial Results and Business Updates WAKIX® (pitolisant) Total Revenue of $45.6 Million for Third Quarter of 2020 Differentiated Product Profile Aligns with Unmet Medical Need On Track to Initiate Phase 2 Trial in Patients with...